Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Ovid Therapeutics (OVID) reported a Q3 loss of $0.20 per share, slightly missing the Zacks Consensus Estimate of a $0.19 loss. However, the company exceeded revenue expectations.
November 12, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ovid Therapeutics reported a Q3 loss of $0.20 per share, missing the consensus estimate by $0.01. Despite this, the company exceeded revenue expectations.
The slight miss in EPS compared to estimates is a negative factor, but the fact that revenue exceeded expectations is a positive. These mixed results may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100